MiMedx settles patent dispute for $25M license deal

The FTC issued a Second Request for more information on MiMedx's (MDXG) acquisition of Sanara (SMTI), delaying the merger beyond the year-end target. SMTI shares fell 5.5%, dropping below their 50-day moving average, while MDXG shares declined 2.8%. The deal, valued at $35 per share, aims to create a larger regenerative medicine company with $400M revenue expected in FY2027.

Sanara MedTech (SMTI) received a Second Request from the FTC, extending the HSR waiting period for its merger with MiMedx. The waiting period will last until 30 days after substantial compliance, unless extended or terminated. The merger's completion is contingent on this waiting period and other closing conditions. Sanara MedTech is cooperating with the FTC.

MiMedx Group (MDXG) received a Second Request from the FTC on Oct 15, 2026, extending the HSR waiting period for its merger with Sanara. The company is cooperating and notes potential risks regarding timing and benefits. Completion depends on ending the waiting period and meeting other conditions.

MIMEDX GROUP, INC. (MDXG) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously announced, MiMedx Group, Inc., a Florida corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Sanara MedTech Inc., a Texas corporation (“Sanara”), and Mustang Merger Sub, Inc., a wholly-owned

Sanara MedTech (SMTI) seeks shareholder approval for a merger with MiMedx. Shareholders will receive $33.00 in cash plus 0.4735 MiMedx shares per Sanara share, valued at roughly $35 per share. The merger requires shareholder approval at a September 30 meeting, with key shareholders already committing their votes in favor.

Sanara MedTech (SMTI) agreed to be acquired by MiMedx Group. The deal, announced on July 29, 2026, is expected to close by year-end, subject to regulatory approvals and other conditions. Both companies will operate independently until the transaction is finalized.